FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2940422877> ?p ?o ?g. }

• W2940422877 endingPage "166" @default.
• W2940422877 startingPage "158" @default.
• W2940422877 abstract "Background Almost 80% of patients with end-stage renal disease (ESRD) initiate dialysis via a central venous catheter (CVC). CVCs are associated with multiple complications and a high cost of care. The purpose of our project is to determine the impact of early cannulation arteriovenous grafts (ECAVGs) on quality of care and costs. Methods The dialysis access modality, complications, secondary interventions, hospital outcomes, and detailed costs were tracked for 397 sequential patients who underwent access creation between July 2014 and October 2018. Complications were grouped into deep vein thrombosis, line infections, sepsis, pneumothorax, and other. Secondary interventions included angioplasty, angioplasty and stent grafting, thrombectomy, surgical revision, and explantation. Hospital outcomes included length of stay, inpatient mortality, 30-day readmission, and discharge disposition. Costs included supplies, medications, laboratory tests, labor, and other direct costs. All variables were measured at the time of the index procedure, 30 days, 90 days, 180 days, 270 days, 1 year, 18 months, and 2 years. Results There were 131 patients who underwent arteriovenous fistula (AVF) and 266 who received ECAVG for dialysis access. The total cost of care per patient was $17,523 for AVF and $5,894 for ECAVG at 1 year (P < 0.01). Primary-assisted patency for AVF was 49.3% versus 81.4% for ECAVG (P = 0.027), and secondary-assisted patency for AVF was 63.8% versus 85.4% for ECAVG at 1 year (P = 0.011). There was a survival advantage for ECAVGs at 1 year (78.6% for AVF vs 85.0% for ECAVG, P = 0.034). Patients who received ECAVG had fewer CVC days (2.3% vs 19.1% for AVF, P < 0.001), fewer complications (1.6% vs. 21.5% for AVF, P < 0.001), and fewer secondary interventions (17.0% vs 52.5% for AVF, P < 0.001). Conclusions This is the first study on patients with ESRD to report detailed outcomes and cost analysis as it relates to AVF versus ECAVG. ECAVGs have an advantage over AVFs due to lower overall cost and better clinical outcomes at 1 year. Implementation of an urgent start dialysis access program centered around ECAVGs may help achieve the national goal of better health care at a lower cost for patients with ESRD. Almost 80% of patients with end-stage renal disease (ESRD) initiate dialysis via a central venous catheter (CVC). CVCs are associated with multiple complications and a high cost of care. The purpose of our project is to determine the impact of early cannulation arteriovenous grafts (ECAVGs) on quality of care and costs. The dialysis access modality, complications, secondary interventions, hospital outcomes, and detailed costs were tracked for 397 sequential patients who underwent access creation between July 2014 and October 2018. Complications were grouped into deep vein thrombosis, line infections, sepsis, pneumothorax, and other. Secondary interventions included angioplasty, angioplasty and stent grafting, thrombectomy, surgical revision, and explantation. Hospital outcomes included length of stay, inpatient mortality, 30-day readmission, and discharge disposition. Costs included supplies, medications, laboratory tests, labor, and other direct costs. All variables were measured at the time of the index procedure, 30 days, 90 days, 180 days, 270 days, 1 year, 18 months, and 2 years. There were 131 patients who underwent arteriovenous fistula (AVF) and 266 who received ECAVG for dialysis access. The total cost of care per patient was $17,523 for AVF and $5,894 for ECAVG at 1 year (P < 0.01). Primary-assisted patency for AVF was 49.3% versus 81.4% for ECAVG (P = 0.027), and secondary-assisted patency for AVF was 63.8% versus 85.4% for ECAVG at 1 year (P = 0.011). There was a survival advantage for ECAVGs at 1 year (78.6% for AVF vs 85.0% for ECAVG, P = 0.034). Patients who received ECAVG had fewer CVC days (2.3% vs 19.1% for AVF, P < 0.001), fewer complications (1.6% vs. 21.5% for AVF, P < 0.001), and fewer secondary interventions (17.0% vs 52.5% for AVF, P < 0.001). This is the first study on patients with ESRD to report detailed outcomes and cost analysis as it relates to AVF versus ECAVG. ECAVGs have an advantage over AVFs due to lower overall cost and better clinical outcomes at 1 year. Implementation of an urgent start dialysis access program centered around ECAVGs may help achieve the national goal of better health care at a lower cost for patients with ESRD." @default.
• W2940422877 created "2019-04-25" @default.
• W2940422877 creator A5020874464 @default.
• W2940422877 date "2019-08-01" @default.
• W2940422877 modified "2023-10-10" @default.
• W2940422877 title "Two-Year Outcomes of Early Cannulation Arteriovenous Grafts for End-Stage Renal Disease" @default.
• W2940422877 cites W1515755080 @default.
• W2940422877 cites W1554927756 @default.
• W2940422877 cites W1989890201 @default.
• W2940422877 cites W1993113814 @default.
• W2940422877 cites W1999608408 @default.
• W2940422877 cites W2117199608 @default.
• W2940422877 cites W2467236735 @default.
• W2940422877 cites W2544286831 @default.
• W2940422877 cites W2588417682 @default.
• W2940422877 cites W2610060833 @default.
• W2940422877 cites W2622472696 @default.
• W2940422877 cites W2734483105 @default.
• W2940422877 cites W2735847656 @default.
• W2940422877 cites W2792766188 @default.
• W2940422877 cites W2805951395 @default.
• W2940422877 cites W2807227018 @default.
• W2940422877 cites W2889817815 @default.
• W2940422877 doi "https://doi.org/10.1016/j.avsg.2019.02.007" @default.
• W2940422877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31009720" @default.
• W2940422877 hasPublicationYear "2019" @default.
• W2940422877 type Work @default.
• W2940422877 sameAs 2940422877 @default.
• W2940422877 citedByCount "6" @default.
• W2940422877 countsByYear W29404228772020 @default.
• W2940422877 countsByYear W29404228772021 @default.
• W2940422877 countsByYear W29404228772022 @default.
• W2940422877 crossrefType "journal-article" @default.
• W2940422877 hasAuthorship W2940422877A5020874464 @default.
• W2940422877 hasConcept C126322002 @default.
• W2940422877 hasConcept C141071460 @default.
• W2940422877 hasConcept C2778063415 @default.
• W2940422877 hasConcept C2779063477 @default.
• W2940422877 hasConcept C2779978075 @default.
• W2940422877 hasConcept C2780326628 @default.
• W2940422877 hasConcept C2781454130 @default.
• W2940422877 hasConcept C3019040382 @default.
• W2940422877 hasConcept C71924100 @default.
• W2940422877 hasConceptScore W2940422877C126322002 @default.
• W2940422877 hasConceptScore W2940422877C141071460 @default.
• W2940422877 hasConceptScore W2940422877C2778063415 @default.
• W2940422877 hasConceptScore W2940422877C2779063477 @default.
• W2940422877 hasConceptScore W2940422877C2779978075 @default.
• W2940422877 hasConceptScore W2940422877C2780326628 @default.
• W2940422877 hasConceptScore W2940422877C2781454130 @default.
• W2940422877 hasConceptScore W2940422877C3019040382 @default.
• W2940422877 hasConceptScore W2940422877C71924100 @default.
• W2940422877 hasLocation W29404228771 @default.
• W2940422877 hasLocation W29404228772 @default.
• W2940422877 hasOpenAccess W2940422877 @default.
• W2940422877 hasPrimaryLocation W29404228771 @default.
• W2940422877 hasRelatedWork W2111350848 @default.
• W2940422877 hasRelatedWork W2146862888 @default.
• W2940422877 hasRelatedWork W2164777106 @default.
• W2940422877 hasRelatedWork W2348846018 @default.
• W2940422877 hasRelatedWork W2384839493 @default.
• W2940422877 hasRelatedWork W2605509226 @default.
• W2940422877 hasRelatedWork W2765672022 @default.
• W2940422877 hasRelatedWork W2946779694 @default.
• W2940422877 hasRelatedWork W2997301945 @default.
• W2940422877 hasRelatedWork W4380489671 @default.
• W2940422877 hasVolume "59" @default.
• W2940422877 isParatext "false" @default.
• W2940422877 isRetracted "false" @default.
• W2940422877 magId "2940422877" @default.
• W2940422877 workType "article" @default.